From the Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C.), and the Duke Human Vaccine Institute, Duke University School of Medicine, Durham (B.F.H.) — both in North Carolina; the University of Alabama at Birmingham, Birmingham (G.M.S.); and the Weatherall Institute of Molecular Medicine and the National Institute for Health Research Biomedical Research Centre, Oxford University, Oxford, United Kingdom (A.J.M.). Address reprint requests to Dr. Cohen at 2031 Bioinformatics Bldg., 130 Mason Farm Rd., Chapel Hill, NC 27517, or at [email protected].
Supported by the National Institutes of Health and the Center for HIV-AIDS Vaccine Immunology.
Dr. Cohen reports receiving consulting fees from GlaxoSmithKline and Merck; Dr. McMichael, receiving payment for the development of educational presentations from Henry Stewart Talks; and Dr. Haynes, receiving a research grant from Peregrine Pharmaceuticals. No other potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank Joseph Sodroski, Norman Letvin, David Goldstein, Kelly Soderberg, Kimberly Powers, Stuart Shapiro, and Margaret Johnston for helpful discussions and Ward Cates, David Burns, Joseph Eron, and William Miller for their careful review of an earlier version of the manuscript.
